RESEARCH · GLOW BLEND · CORNEA AND OCULAR SURFACE
GLOW BLEND Components in Corneal and Ocular Surface Research: Thymosin Beta-4 Trials, BPC-157 Rat Models and a GHK-Cu Question
PurixLab’s GLOW BLEND 70mg is a research vial with the labelled composition BPC-157 10mg + TB-500 10mg + GHK-Cu 50mg. Our earlier articles cover the composition and component overview, thymosin beta-4 and actin sequestration, the combination and copper-chemistry questions, dermal wound-healing models and hair follicle models. This article looks at the eye, specifically the cornea and ocular surface, where one component has reached randomised clinical trials, a second has a cluster of rat studies from a single group, and the third has an old finding that points in the opposite direction on blood vessels. The material is supplied for laboratory research use only, and nothing here describes effects of any PurixLab product.
Why the cornea is a distinctive model
The healthy cornea is transparent and has no blood vessels, a state often called angiogenic privilege. Healing a corneal wound therefore has to restore the epithelium while avoiding new vessel growth, scarring and loss of corneal nerves. Reviews from the BPC-157 group frame corneal ulcer healing, corneal neovascularisation and intraocular pressure as a linked “triad” [1]. That framing matters here, because a component that promotes angiogenesis in skin may be unwelcome in the cornea.
Thymosin beta-4: from cell migration to clinical trials
In human corneal epithelial cells, thymosin beta-4 increased expression of the laminin-5 gamma2 chain, a basement membrane protein involved in epithelial migration, and did so independently of TGF-beta 1 [2]. A review by Sosne and Kleinman summarises the proposed mechanisms of cell migration, reduced inflammation and cytoprotection in eye injury models [3].
Thymosin beta-4 eye drops (RGN-259) then entered clinical testing. In a small phase 2 trial of nine patients with severe dry eye, the treated group showed a 35.1% reduction in ocular discomfort and a 59.1% reduction in corneal fluorescein staining versus vehicle at day 56 [4]. A larger phase II trial of 72 subjects in a controlled adverse environment model did not meet either primary endpoint, although some secondary measures differed, including a 27% reduction in discomfort scores during the day 28 challenge [5]. In a mouse dry eye model, RGN-259 was compared with cyclosporine A, diquafosol and lifitegrast and was reported as equal to or more effective than these drugs on several measures [6].
For neurotrophic keratopathy, a phase 3 trial reported complete healing at 4 weeks in 6 of 10 treated subjects versus 1 of 8 on placebo (p = 0.0656), a trend that did not reach significance [7]. A 2025 Cochrane review rated this result as low-certainty evidence, with a risk ratio of 9.00 and a 95% confidence interval from 0.57 to 141.88 in 18 participants [8].
Thymosin beta-4 in infection and injury models
One laboratory has studied thymosin beta-4 as an add-on to ciprofloxacin in Pseudomonas aeruginosa keratitis in mice. The combination improved disease outcome compared with either agent alone, with changes in inflammatory and wound-healing mediators [9]. Later work linked the effect to specialised pro-resolving lipid mediator pathways [10] and reported restored visual acuity, contrast sensitivity, corneal sensitivity and nerve density with the combination [11]. In rabbit corneal alkali burns, a glycine-extended analogue, Gly-thymosin beta-4, inhibited corneal neovascularisation and improved epithelial recovery [12]. An engineered tandem peptide with two G-actin binding domains healed alkali-injured mouse corneas with less scarring than the native molecule [13].
None of these studies used TB-500. TB-500 was identified by mass spectrometry as the N-terminally acetylated 17-23 fragment of thymosin beta-4, Ac-LKKTETQ [14], while the corneal work used the full-length protein, RGN-259 or engineered variants.
BPC-157: corneal wounds, glaucoma and retinal models in rats
In 48 rats with total corneal epithelial debridement, topical BPC-157 accelerated closure of the defects, which disappeared by 40 hours at the highest concentration, with effects graded by concentration [15]. After a perforating corneal incision, BPC-157-treated eyes regained transparency, epithelial defects closed by 72 hours at the highest concentration, and treated rats generally had no new vessels reaching the wound [16].
The same group reported that BPC-157 normalised intraocular pressure and preserved retinal ganglion cells and the optic nerve in a rat glaucoma model produced by cauterising episcleral veins [17], and counteracted retinal ischaemia induced by retrobulbar L-NAME [18]. These results come from one research group with overlapping authors [15,16,17,18,1], and we found no published controlled human eye study of BPC-157.
GHK-Cu and corneal blood vessels: a tension
The GHK-Cu data point the other way. In a classic rabbit cornea assay, glycyl-L-histidyl-L-lysine induced new capillary formation when bound to copper, as did ceruloplasmin and heparin, while the copper-free molecules did not [19]. Thymosin beta-4 analogue and BPC-157 studies, by contrast, reported reduced corneal neovascularisation [12,16]. In our PubMed searches we did not find a corneal wound-healing study of GHK-Cu itself, so its net effect on the ocular surface remains untested.
Reading this literature critically
- One molecule has human data. Only thymosin beta-4 eye drops have randomised trials, which were small and mixed [4,5,7], and the Cochrane review rated the evidence as low certainty [8].
- Single-group findings. The BPC-157 eye studies all come from one group [1], and much of the thymosin beta-4 keratitis work also comes from one laboratory [9,10,11].
- No blend data. No study has tested the three components together on the eye, and the opposing vessel findings [19,16] mean the combination cannot be predicted from the parts.
What remains open
- Whether the TB-500 fragment shares any of the corneal activity reported for the full-length protein.
- Whether copper-bound GHK promotes or limits vessel growth in an injured cornea.
- Whether the BPC-157 rat results replicate in an independent laboratory.
GLOW BLEND 70mg at PurixLab
GLOW BLEND 70mg: a labelled lyophilized research vial combining BPC-157, TB-500 and GHK-Cu (10mg + 10mg + 50mg, 70mg total per vial), C$136 per vial (CAD, before tax), supplied for laboratory research only. Batch documentation is available on request. Product page: purixlab.com/product/glow-blend-70mg/.
PurixLab ships within Canada only, from stock held in Toronto. Standard shipping is C$15, and shipping is free when the product subtotal is C$200 or more after discounts. Orders outside the GTA ship by Canada Post Xpresspost. Prices are in CAD and taxes are calculated from your shipping address at checkout.
In Toronto and the GTA, our own team delivers orders the same day or the next day. There is no fixed GTA delivery fee: after you place your order, we email you to confirm the delivery time and any delivery charge, and then you pay. There is no storefront or local pickup.
Payment is by Interac e-Transfer (instructions are shown at checkout) or by cryptocurrency through Plisio (Bitcoin, Ethereum, USDT and more): choose Plisio at checkout and you are sent to a secure Plisio payment page after placing the order. Current offers and any pack pricing are shown on the product page and in your cart; offers do not stack.
For laboratory research use only. Not for human or veterinary use, not for consumption, injection or application to skin, and purchasers must be 18 or older. The studies summarised above describe specific materials in published research; they are not claims about any PurixLab product.
Questions or batch documentation requests: [email protected] · Shipping & Delivery · Toronto & GTA delivery · PurixLab FAQ
References
- Masnec S, Kokot A, Kralj T, et al. Challenge of Corneal Ulcer Healing: A Novel Conceptual Framework, the "Triad" of Corneal Ulcer Healing/Corneal Neovascularization/Intraocular Pressure, and Avascular Tendon Healing, for Evaluation of Corneal Ulcer Therapy, Therapy of Neovascularization, Glaucoma Therapy, and Pentadecapeptide BPC 157 Efficacy. Pharmaceuticals (Basel). 2025;18(12):1822. PubMed 41471311 · PMC12735534 · doi:10.3390/ph18121822
- Sosne G, Xu L, Prach L, et al. Thymosin beta 4 stimulates laminin-5 production independent of TGF-beta. Exp Cell Res. 2004;293(1):175-83. PubMed 14729067 · doi:10.1016/j.yexcr.2003.09.022
- Sosne G, Kleinman HK. Primary Mechanisms of Thymosin β4 Repair Activity in Dry Eye Disorders and Other Tissue Injuries. Invest Ophthalmol Vis Sci. 2015;56(9):5110-7. PubMed 26241398 · doi:10.1167/iovs.15-16890
- Sosne G, Dunn SP, Kim C. Thymosin β4 significantly improves signs and symptoms of severe dry eye in a phase 2 randomized trial. Cornea. 2015;34(5):491-6. PubMed 25826322 · doi:10.1097/ICO.0000000000000379
- Sosne G, Ousler GW. Thymosin beta 4 ophthalmic solution for dry eye: a randomized, placebo-controlled, Phase II clinical trial conducted using the controlled adverse environment (CAE™) model. Clin Ophthalmol. 2015;9:877-84. PubMed 26056426 · PMC4445951 · doi:10.2147/OPTH.S80954
- Kim CE, Kleinman HK, Sosne G, et al. RGN-259 (thymosin β4) improves clinically important dry eye efficacies in comparison with prescription drugs in a dry eye model. Sci Rep. 2018;8(1):10500. PubMed 30002412 · PMC6043477 · doi:10.1038/s41598-018-28861-5
- Sosne G, Kleinman HK, Springs C, et al. 0.1% RGN-259 (Thymosin ß4) Ophthalmic Solution Promotes Healing and Improves Comfort in Neurotrophic Keratopathy Patients in a Randomized, Placebo-Controlled, Double-Masked Phase III Clinical Trial. Int J Mol Sci. 2022;24(1):554. PubMed 36613994 · PMC9820614 · doi:10.3390/ijms24010554
- Kruoch Z, Choo AY, Kemp A, et al. Medical and surgical interventions for neurotrophic keratopathy. Cochrane Database Syst Rev. 2025;12(12):CD015723. PubMed 41347649 · doi:10.1002/14651858.CD015723.pub2
- Carion TW, Ebrahim AS, Kracht D, et al. Thymosin Beta-4 and Ciprofloxacin Adjunctive Therapy Improves Pseudomonas aeruginosa-Induced Keratitis. Cells. 2018;7(10):145. PubMed 30241380 · PMC6210523 · doi:10.3390/cells7100145
- Wang Y, Banga L, Ebrahim AS, et al. Activation of pro-resolving pathways mediate the therapeutic effects of thymosin beta-4 during Pseudomonas aeruginosa-induced keratitis. Front Immunol. 2024;15:1458684. PubMed 39380984 · PMC11458456 · doi:10.3389/fimmu.2024.1458684
- Ebrahim AS, Liu L, Carion TW, et al. Reparative Outcomes in Corneal Infection: Linking Adjunctive Tβ4 Treatment to Nerve Regeneration and Visual Function. Invest Ophthalmol Vis Sci. 2026;67(6):22. PubMed 42283548 · PMC13274770 · doi:10.1167/iovs.67.6.22
- Zhang W, Nie L, Du L, et al. Topical treatment of corneal alkali burns with Gly-thymosin β4 solutions and in situ hydrogels via inhibiting corneal neovascularization and improving corneal epidermal recovery in experimental rabbits. Burns. 2017;43(8):1742-1747. PubMed 28602595 · doi:10.1016/j.burns.2017.05.002
- Nguyen J, Verma S, Vuong VT, et al. Engineered Tandem Thymosin Peptide Promotes Corneal Wound Healing. Invest Ophthalmol Vis Sci. 2025;66(14):31. PubMed 41235866 · PMC12636994 · doi:10.1167/iovs.66.14.31
- Esposito S, Deventer K, Goeman J, et al. Synthesis and characterization of the N-terminal acetylated 17-23 fragment of thymosin beta 4 identified in TB-500, a product suspected to possess doping potential. Drug Test Anal. 2012;4(9):733-8. PubMed 22962027 · doi:10.1002/dta.1402
- Lazić R, Gabrić N, Dekaris I, et al. Gastric pentadecapeptide BPC 157 promotes corneal epithelial defects healing in rats. Coll Antropol. 2005;29(1):321-5. PubMed 16117343
- Masnec S, Kokot A, Zlatar M, et al. Perforating corneal injury in rat and pentadecapeptide BPC 157. Exp Eye Res. 2015;136:9-15. PubMed 25912999 · doi:10.1016/j.exer.2015.04.016
- Kralj T, Kokot A, Zlatar M, et al. Stable Gastric Pentadecapeptide BPC 157 Therapy of Rat Glaucoma. Biomedicines. 2021;10(1):89. PubMed 35052769 · PMC8773185 · doi:10.3390/biomedicines10010089
- Zlatar M, Kokot A, Vuletic LB, et al. BPC 157 as a Therapy for Retinal Ischemia Induced by Retrobulbar Application of L-NAME in Rats. Front Pharmacol. 2021;12:632295. PubMed 34177567 · PMC8222724 · doi:10.3389/fphar.2021.632295
- Raju KS, Alessandri G, Ziche M, et al. Ceruloplasmin, copper ions, and angiogenesis. J Natl Cancer Inst. 1982;69(5):1183-8. PubMed 6182332